Zhao Wensi, Huang Zhen
Department of Clinical Oncology, Renmin Hospital of Wuhan University Wuhan 430060, Hubei, China.
Am J Transl Res. 2023 Apr 15;15(4):2918-2925. eCollection 2023.
Immunotherapy has changed the landscape of contemporary cancer treatment. Different from microsatellite instability-high colorectal cancer (CRC), the microsatellite-stable (MSS) CRC shows little response to immunomonotherapy. Reasonable drug combinations may be a valuable exploration to solve this the dilemma. Here, we report a young patient with refractory metastatic rectal adenocarcinoma at stage IVb who achieved a durable partial response after receiving tislelizumab plus fruquintinib and well-timed local radiotherapy. To date, the patient has a progression-free survival of more than 12 months with obviously declined serum tumor markers, increased peripheral blood effector T cells, alleviated scrotal edema and improved quality of life. This case suggests that an immune checkpoint inhibitor combined with an anti-VEGFR-tyrosine kinase inhibitor and local radiation intervention might be an effective strategy for heavily pretreated metastatic CRC patients with MSS phenotype.
免疫疗法已经改变了当代癌症治疗的格局。与微卫星高度不稳定型结直肠癌（CRC）不同，微卫星稳定（MSS）型CRC对免疫单药治疗反应甚微。合理的药物联合可能是解决这一困境的有价值探索。在此，我们报告一名IVb期难治性转移性直肠腺癌年轻患者，其在接受替雷利珠单抗联合呋喹替尼并适时进行局部放疗后获得了持久的部分缓解。迄今为止，该患者无进展生存期超过12个月，血清肿瘤标志物明显下降，外周血效应T细胞增加，阴囊水肿减轻，生活质量改善。该病例提示，免疫检查点抑制剂联合抗血管内皮生长因子受体酪氨酸激酶抑制剂及局部放疗干预可能是MSS表型的经大量预处理的转移性CRC患者的有效策略。
